Increasing Longevity by Unlocking Medicines Targeting Abnormal
LIpid MEtabolism

At Lime, we are inventing breakthrough lipid-targeting therapeutics using our novel drug discovery platform.

Lime Therapeutics is a fast-growing biotechnology company focused on making a difference for patients. We are a spinout company developing new technology invented at Memorial Sloan Kettering Cancer Center, and are using our breakthrough LipidSense™ platform to hunt for novel targets and create new drugs that modulate aberrant lipid metabolism in many forms of cancer, metabolic diseases, and neurodegenerative disorders.

Intro

Leadership

Leadership Team

Scientific Advisory Board

Robert Schwartz, MD, PhD

Weill Cornell Medicine

Matthew
Vander Heiden, MD, PhD

Massachusetts Institute of Technology (MIT)

Rushika Perera, PhD

University of California,
San Francisco

Xuejun Jiang, PhD

Tuomas Tammela, MD, PhD

Memorial Sloan Kettering Cancer Center

Business Advisors

Jeff Hatfield, MBA

Robin Mansukhani

CEO, Deciduous Therapeutics

Chairman of the Board of Directors, Vividion Therapeutics, and Harvard Blavatnik Fellow Advisor

Parul Chachra, PhD, MBA

X (Google)

Team

SAB

Biz Advisors

Technology

Creating Lipid-Altering Therapeutics

Cancers feed off nutrients, such as lipids (fats). In addition, excess lipid buildup is a hallmark of neurodegenerative disorders. Despite this, efforts to target lipid metabolism in cancer and neurodegenerative disorders have remained elusive due to lack of technology.

We've changed the game with the invention of an ultrasensitive lipid detection technology. LipidSense is a high-throughput screening platform that monitors lysosomal lipid flux in real time in live cells, in a well-plate format, and in live animals.

We can tell within seconds whether a particular therapy changes lipid flux. We are utilizing this platform to discover drugs that can alter cancer's access to lipids or restore lysosomal lipid function in neurodegenerative disorders.

The primary indication for our lead drug candidate is non-small cell lung cancer. We are also exploring therapeutic opportunities for this and other drugs in our pipeline for pancreatic, colorectal, and kidney cancer. Collectively, these four cancers represent a $50B total addressable market (TAM) and 462,000 patients diagnosed annually in the US.